Arana's pilot for arthritis
Wednesday, 26 November, 2008
Arana Therapeutics has sought approval for a small dose regimen study of its lead inflammatory disease candidate ART621 in rheumatoid arthritis.
The study, to be conducted in Sri Lanka and enrolling 20 patients, will compare four different dose regimens in order to optimise the regimen for its international Phase II dose ranging study.
Arana’s acting CEO Dr Steffen Nock said in an ASX statement that the data gathered from the small study will help fine-tune the larger one.
He said data from the company’s study of ART621 in psoriasis was due early next year.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
